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Healthcare workers (HCWs) play a central role in global tuberculosis (TB) elimination efforts but 
their contributions are undermined by occupational TB. HCWs have higher rates of latent and 
active TB than the general population due to persistent occupational TB exposure, particularly in 
settings where there is a high prevalence of undiagnosed TB in healthcare facilities and TB 
infection control (TB-IC) programmes are absent or poorly implemented. Occupational health 
programmes in high TB burden settings are often weak or non-existent and thus data that record 
the extent of the increased risk of occupational TB globally are scarce. HCWs represent a limited 
resource in high TB burden settings and occupational TB can lead to workforce attrition. Stigma 
plays a role in delayed diagnosis, poor treatment outcomes and impaired wellbeing in HCWs who 
develop TB. Ensuring the prioritization and implementation of TB-IC interventions and 
occupational health programmes, which include robust monitoring and evaluation, is critical to 
reduce nosocomial TB transmission to patients and HCWs. The provision of preventive therapy 
for HCWs with latent TB infection can also prevent progression to active TB. Unlike other patient 
groups, HCWs are in a unique position to serve as agents of change to raise awareness, advocate 
for necessary resource allocation and implement TB-IC interventions, with appropriate support 
from dedicated TB-IC officers at the facility and national TB programme level. Students and 
community health workers (CHWs) must be engaged and involved in these efforts. Nosocomial 
TB transmission is an urgent public health problem and adopting rights-based approaches can be 
helpful. However, these efforts cannot succeed without increased political will, supportive legal 
frameworks and financial investments to support HCWs in efforts to decrease TB transmission.
INTRODUCTION
Tuberculosis (TB) is now the leading cause of adult death globally from an infectious 
disease, surpassing HIV and malaria1. Moreover, TB is airborne, with the main risk activity 
being breathing. Although healthcare workers (HCWs) have a central role in global TB 
elimination efforts, their contributions are undermined by the risk of occupational TB. The 
2016 WHO Global TB Report estimates that, in 2015, the number of TB cases per 100 000 
HCWs was more than double the notification rate in the general adult population1. The risk 
of TB transmission in healthcare and other congregate settings is high2,3 and nosocomial 
outbreaks of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-
TB) are well documented4,5. TB infection control (TB-IC) is one of the key components of 
the second pillar of the WHO End TB Strategy6. However, limited attention and resources 
are applied to TB-IC at both the facility and national level, resulting in ongoing nosocomial 
TB transmission2,7. This review will discuss some of the major challenges and potential 
solutions to improve TB-IC efforts with a focus on the role of HCWs, although it is 
important to emphasize that the risks of nosocomial TB transmission also apply to patients. 
We start by describing three cases that demonstrate the current reality of occupational TB 
across HCW groups in high TB burden countries (HBCs).
Case 1 – Russia
A medical student remembered finding it difficult to breathe the first time she wore a 
surgical mask in the operating theatre. Outside the theatre, the doctors who taught her did 
not wear respirators and so she learnt not to do so either. The risks of occupational TB were 
never discussed, although she was aware that a medical student and a lecturer had previously 
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fallen ill from multidrug-resistant (MDR) TB. She remembered the shock she felt when she 
received her MDR-TB diagnosis as an intern in her hometown in Malaysia, after completing 
medical school in Russia. She felt particularly lonely and struggled to come to terms with 
her diagnosis. In Russia and other Eastern European countries, HCWs have been 
demonstrated to be up to three times more likely to develop TB (including MDR-TB) than 
the general population, with the risk demonstrated to be up to 30–90 times higher for 
clinicians employed in TB-specific facilities8.
Case 2 – South Africa
A nurse worked in a privately owned dialysis unit. She had trained and worked in both 
public and private sector healthcare facilities in South Africa throughout her career but 
although she had cared for countless patients with TB, she never thought that she herself 
would be at such high risk. Looking back, she noted that the ventilation in the dialysis unit 
was poor with no open windows and TB testing or existing diagnoses for patients were never 
discussed. However, when she developed MDR-TB, she was made to feel like she had done 
something wrong and was very much affected by the stigma of TB. Although she is 
extremely grateful to have survived occupational MDR-TB, she developed hearing loss due 
to aminoglycoside therapy and has been left with post-TB bronchiectasis, which causes 
frequent exacerbations and impaired lung function. To her knowledge, infection control 
practices in the dialysis unit have not changed. A recent systematic review demonstrated 
high rates of latent and active TB in South African HCWs although available data were 
limited9.
Case 3 – India
In November 2015, a senior laboratory technician at a major hospital in Mumbai became the 
fourth HCW to die from MDR-TB that year. Having diabetes put him at a higher risk of 
acquiring TB and having a worse outcome from TB but it is unlikely that he had ever 
received testing or treatment for latent TB. Despite having no direct contact with patients, 
laboratory staff have an increased risk of developing TB due to exposure to sputum 
specimens if correct biosafety procedures including wearing personal protective equipment 
(PPE) are not strictly implemented. Deaths have also been noted in other non-clinical staff 
including ward attendants and cleaning staff. Despite the adoption of national airborne 
infection control guidelines in India, site visits have demonstrated that TB-IC is frequently 
poorly developed and implemented10.
CHALLENGES
The epidemiology of TB in HCWs
HCWs globally are at increased risk for TB infection and disease, although rates of 
occupationally acquired TB are highest in low- and middle-income countries (LMICs)2,11. 
In these settings, drug-resistant TB (DR-TB) also affects HCWs at a greater frequency than 
the communities they serve12,13. The increased risk of TB affects all healthcare personnel 
including community health workers (CHWs), clinical support staff, laboratory workers and 
health science students14,15. Clinical staff (nurses and doctors) appear to be at highest 
risk16,17. However there is a dearth of data regarding other groups such as ancillary support 
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and administrative staff who may work in clinical areas and CHWs, although at least some 
studies have demonstrated that these groups are also at considerable risk.9,18–20 Although 
HCWs in LMICs may also be at high risk of TB exposure in their communities, studies that 
have controlled for living conditions confirm additional risk of TB disease attributable to 
workplace TB exposure21. The documented 3 to 6-fold increased risk of TB is due to 
persistent occupational TB exposure in the setting of absent or poorly implemented TB 
infection control (TB-IC) programmes2,11 and a high prevalence of undiagnosed TB in 
healthcare facilities22,23. Ironically, accurate data on TB exposure and infection risk in 
HCWs is most limited from settings with highest TB burden9,24. Possible factors explaining 
the paucity of occupational TB data include the lack of national HCW TB surveillance, 
weak or non-existent occupational health programmes, reluctance among HCWs to disclose 
a TB diagnosis owing to stigma and the challenge of diagnosing latent TB infection in TB 
endemic settings25. In some countries, the close association of TB and HIV disease 
aggravates stigma surrounding a TB diagnosis, resulting in diagnostic and treatment delays 
among HCWs25. The risk of occupationally acquired TB and the adverse consequences for 
infected HCWs contribute to attrition of HCWs in regions already challenged by severe 
shortages in human resources for health26,27.
TB Infection Control Gaps
Poorly ventilated and overcrowded indoor congregate settings where there are people with 
infectious but unsuspected TB, such as healthcare facilities, may be responsible for a high 
proportion of TB transmission in HBCs3. To address the risk of nosocomial TB 
transmission, the World Health Organization (WHO) has proposed the adoption and rigorous 
implementation of TB-IC measures28. These guidelines divide TB-IC measures into 
different types. Managerial TB-IC measures include leadership and commitment to establish 
and implement infection control policies at the health facility level29. Administrative control 
measures include the prompt identification and separation of persons with probable TB, 
emphasizing timely diagnosis and treatment of active TB30. Environmental measures include 
optimized operational structures, including building design and patient flow to decrease the 
concentration of airborne TB droplet nuclei and to control the directional flow of potentially 
infectious aerosols31. Personal protective TB-IC measures focus on the provision of 
correctly fitted respirators31. However even if respirators are available, respirator fit testing 
is often not performed and thus wearing respirators incorrectly offers a false sense of 
security32. Additionally respiratory protection is typically only worn in instances where 
patients are being evaluated for known or suspected TB and therefore cannot offer protection 
from transmission due to unsuspected TB31.
Despite these clear recommendations for TB-IC, studies have consistently demonstrated the 
absence of TB-IC programmes in health-care facilities in HBCs2,33. The lack of 
implementation and scale up of these preventative measures, with an emphasis on rapidly 
diagnosing and treating unsuspected TB, are primarily responsible for nosocomial TB 
transmission10,34,35. In HBCs such as South Africa, poor building design, overcrowding, 
lack of knowledge and training regarding facility-based IC plans and guidelines, and poor 
managerial involvement in the design and implementation of local TB-IC policy have been 
noted as barriers to the implementation of such measures36,37. It should be mentioned that 
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TB-IC is also often neglected in low and medium incidence countries. A standardized survey 
tool used to evaluate drug-resistant TB management in several European countries identified 
the lack of a comprehensive TB-IC plan in all the reference centres surveyed38. 
Administrative and environmental controls in particular were often lacking. Alarmingly 
despite the availability of personal protective equipment (PPE i.e. respirators for staff and 
surgical masks for patients), respirator fit testing was also not available at any of these 
reference centres32.
Lack of Robust Occupational Health Systems
Accurate surveillance and reporting of TB disease in HCWs in LMICs is crucial to gaining a 
better understanding of the epidemiology of TB in this high-risk population39. Although 
WHO published recommendations on their global strategy of occupational health for all in 
199440 and released their 10-year Global Plan of Action for Workers’ Health in 200741, only 
31 countries have ratified the Convention on Occupational Health Services42 and it has been 
estimated that only 5% to 10% of workers in developing countries have access to adequate 
occupational health services43. While the impact of the 2014 Ebola epidemic on the health 
workforce drew attention to the lack of infection control and occupational health services in 
West Africa44, despite having a mortality rate comparable to Ebola and causing illness in an 
estimated 580 000 people annually, DR-TB has not garnered the necessary political will and 
urgency to prioritize the institution and maintenance of occupational health services in TB 
endemic countries.
Challenges with Treatment and Returning to Work
TB treatment, particularly for drug-resistant strains, is daunting. Outcomes for treatment of 
drug-resistant TB in HCWs are poor, with high rates of treatment failure, mortality and 
therapy related morbidity12,13. Although healthcare workers know the rationale for treatment 
and need for adherence, many have commented that they had little understanding of the true 
demands of TB and its treatment regimens and the effect that the disease and the antibiotics 
have on the body until they became patients themselves45. Consultations are often pressed 
for time, leaving little or no time for compassionate conversations that delve into the 
patient’s emotional state or ability to cope with treatment27. For HCWs such as CHWs or 
ancillary staff, as well as foreign HCWs, there may also be language, cultural or educational 
barriers that affect crucial knowledge transfer. Social support networks may be limited. Side 
effects such as peripheral neuropathy, ototoxicity and vision loss may be career-ending for 
HCWs27,45,46. Although HCWs may have better access to healthcare facilities than other 
patients, they may encounter greater stigma and be reluctant to engage in care47. This also 
has implications for their ability to return to work. The psychological and financial costs of 
not being able to return to work may be crippling for HCWs and their families.
Per guidelines from the U.S. Centers for Disease Control, HCWs with TB should be allowed 
to return to work when they 1) have had three negative AFB sputum smear results collected 
8–24 hours apart (at least one of which should be an early morning specimen) and 2) have 
responded to anti-TB treatment that should be effective based on drug susceptibility testing 
results48. The assessment of whether a HCW with TB is no longer infectious and can return 
to work should be made by a physician who has expertise in the management of TB. 
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Notably, HCWs in HBCs are often reluctant to return to healthcare facilities, where they risk 
re-exposure and reinfection27.
Stigma and Occupational TB
Despite romanticized perceptions regarding ‘consumption’ in Victorian times, the language 
that has subsequently been used within the TB community has undoubtedly contributed to 
the stigma associated with this preventable and curable disease. Terms such as ‘TB suspect’ 
and ‘default’ have criminal connotations49 and there has been an increasing emphasis on 
avoiding the use of such stigmatizing terminology. Goffman’s definition of stigma50 was 
reworked and applied to HIV by Alonzo and Reynolds51 who described stigma as being a 
‘powerful discrediting and tainting social label that radically changes the way individuals 
view themselves and are viewed as persons.’ This definition also introduces the concepts of 
external and internal stigma.
External stigma is directed towards HCWs by other HCWs. According to Courtwright the 
commonest cause of stigma is the perceived risk of transmission52. HCWs diagnosed with 
TB are excluded or avoided, often long after the initial high-risk period for transmission. TB 
is also stigmatized because of its connotations with malnutrition, poverty and HIV, which 
may prompt open speculation in the workplace about the affected healthcare worker’s 
immune status53,54.
Internal stigma is directed by HCWs towards themselves. Feelings of isolation and shame 
associated with TB can lead to withdrawal from the community. One of the symbols of the 
contagious nature of TB, and hence also the stigma associated with it, is the mask. 
Interestingly, although masks are worn routinely in some clinical environments like the 
operating theatre and in certain countries when using public transport, patients wearing 
masks to reduce TB transmission report feeling stigmatized and HCWs wearing respirators 
for protection find that this creates a barrier between them and their patients47,55.
There is a need to refine existing TB stigma scales developed for HCWs and measure the 
impact of various strategies to reduce stigma56. Possible interventions include bringing 
affected HCWs together to support each other52 or large-scale community based campaigns 
like the Unmask Stigma campaign that has taken place on World TB day57,58. Addressing 
stigma could have a positive impact on diagnostic delays, treatment outcomes, psychological 
wellbeing and awareness about the prevalence of occupational TB.
SOLUTIONS
TB Infection Control Solutions
The primary aim of the WHO checklist for periodic evaluation of TB-IC in health-care 
facilities is to prevent the transmission of TB to both patients and HCWs59. From a 
management perspective, a TB-IC plan that includes a person responsible for TB-IC and an 
adequate budget for TB-IC activities such as training should be available at all health 
facilities. In addition, all staff should receive TB-IC training at least every two years as 
recommended by the WHO59. Each facility should have administrative IC measures in 
place, such as FAST (Find cases Actively using cough screening and rapid molecular 
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diagnostics, Separate temporarily and promptly Treat effectively)30 and environmental 
control measures such as improving ventilation, decreasing overcrowding and the use of 
germicidal ultraviolet disinfection3,31. These measures should be considered at the outset 
during the health facility planning process and IC officers should thus be part of advisory 
committees to architects designing health facilities to give input on TB-IC measures. 
Although it is essential that HCWs as well as ancillary staff working in patient-care areas 
should have access to N95 respirators that fit them correctly, this should not preclude 
concurrent implementation of administrative TB-IC controls60. Staff shortages and 
inadequate training at facilities where TB is treated should be addressed37. Regular training 
on TB-IC along with monitoring of HCWs’ and institutional adherence to these measures 
should occur, so that areas with poor adherence can be identified and remediated. 
Implementing a comprehensive TB-IC package may seem overwhelming. Prioritizing key 
interventions will be necessary and setting-specific context is important. For example, 
maximizing natural ventilation will be feasible in healthcare facilities in warmer climates but 
in colder climates, interventions such as germicidal ultraviolet air disinfection may yield 
greater benefits31. Establishing reporting systems through which HCWs can document TB-
IC implementation issues that would require attention at the facility and subsequently failing 
that, at the NTP level, could help to bridge the gap between TB-IC policy and practice.
Developing and Strengthening Occupational Health Systems
Occupational health programmes should be prioritized, maintained and rigorously evaluated, 
with an emphasis on computerized data collection to facilitate operational monitoring and 
evaluation61. We advocate that occupation should be added to facility TB patient registers 
and recorded by national TB programmes so that the epidemiology of occupational TB can 
be better understood and enable the prioritization of target interventions39. Regular 
occupational screening for TB should be available at each health facility. This involves 
overcoming challenges such as shortages of tuberculin for skin testing or the costs of 
interferon gamma release assay testing, both of which are used for the diagnosis of latent 
TB. Occupational health programmes in TB endemic settings should also offer HIV testing 
and linkage to care, which should include the provision of isoniazid preventive therapy (IPT) 
for HCWs with HIV. The feasibility of relocating HCWs living with HIV to a lower risk 
clinical area28 is contentious since the majority of clinical areas in HBCs pose a TB 
transmission risk due to the high prevalence of undiagnosed TB.
HCWs (regardless of HIV status) in many low prevalence settings have access to treatment 
for LTBI, an intervention proven over decades to be effective62–64. HCWs in high burden 
settings should therefore also have an opportunity to prevent their progression from infection 
to disease through the provision of LTBI therapy, since the risk of progression is higher in 
high transmission settings. The lack of LTBI treatment for high-risk groups such as HCWS 
represents not only an important gap in TB control efforts but also one that is within the 
power of the current healthcare system itself to remediate. Access to rapid molecular 
diagnostic tests such as Xpert MTB/RIF for active TB diagnosis65 must be ensured so that 
healthcare professionals can be promptly tested if they experience any symptoms of TB and 
start effective therapy based on drug susceptibility testing28. Confidentiality should be 
ensured as far as possible with regards to the outcome of tests, to overcome this barrier to 
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getting tested61, although it is important that this should not preclude contact screening. 
Building robust occupational health systems will be an important component for overall TB 
elimination efforts42.
How can HCWs be Agents of Change?
HCWs should advocate for the adoption of policies aimed at documenting, preventing and 
addressing nosocomial TB transmission. HCWs are in a unique situation, compared to other 
populations who are particularly vulnerable to TB, as they may be able to have greater input 
into developing and implementing such policies to protect not only themselves but also their 
patients39. Although health advocacy has not always been an explicitly expected role for 
HCWs to fulfill, and while many HCWs may view their area of expertise and responsibility 
as clinical, the importance of advocacy was stressed in a commission on global health 
professional education published in The Lancet in 201066 and as part of the CanMEDS 
framework for physician competency67.
One approach designed to engage HCWs to become agents of change has focused on 
sharing relatable stories of HCWs affected by tuberculosis to destigmatize occupational TB 
and dispel the notion that HCWs are “TB Proof”, highlighting the shared risk in healthcare 
facilities45. HCWs can also advocate for testing and treatment for LTBI, which has been a 
neglected issue in HBCs but is now the subject of greater attention. The HCWs described in 
Cases 1 and 2 were both successfully treated for MDR-TB and are now staunch advocates 
for HCW workplace safety focused on TB prevention and destigmatization and are working 
with other agents of change to raise awareness and mobilise the wider HCW community.
The importance of educating and engaging healthcare students
Students training to become health professionals are exposed to the same occupational 
hazards as their professional counterparts and resultantly have a high risk of occupational 
TB68. Although students in endemic settings may report perceiving themselves to be at 
higher risk of TB and are more likely to have received TB-IC training than other HCWs69, 
they are not more likely to provide correct examples of TB-IC measures or to use PPE as 
recommended70,71. Additionally, it is concerning to note that healthcare students have 
indicated that they perceive their professional mentors to be similarly aware of the risks of 
occupational tuberculosis, but report that they do not take the necessary precautions47,69. 
Many professional behaviours are modeled on those of mentors72, and efforts need to be 
made to ensure that safe practices are emphasized in order to form a foundation for future 
practices. Engaging future HCWs during this early stage of their training by focusing some 
intervention efforts on large hospitals that serve as teaching sites can help to facilitate HCWs 
becoming and remaining agents of change (see Figure 1).
Human Rights and the Role of the Law
Legal and regulatory frameworks have a role to play in efforts to decrease TB 
transmission73. There have been scant efforts in highlighting the role and importance of 
human rights in the global TB control efforts. This reflects the absence or poor 
implementation of TB-specific legislation, which can articulate the rights of people with TB, 
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the risk of TB in nosocomial settings and the harms of stigma and discrimination, in TB 
endemic countries74.
With regards to TB-IC, the global health community lacks a sound understanding of the 
law’s effect on population health. Although the existence of laws and regulations does not 
ensure that they will be implemented, they provide a structural framework to guide TB-IC 
efforts. Consequently, a better understanding of the existing laws that address TB-IC is a 
prerequisite to assessing their implementation and their effect on practice. A review of laws 
and regulations described and analysed legislative approaches to TB infection control 
practices in Botswana, South Africa and Zambia, focusing on selected elements of WHO’s 
TB-IC policy75. In all three countries, TB case reporting is required, as is TB surveillance 
among HCWs. Each country’s legal and regulatory framework also addresses the need to 
respect individuals’ rights and privacy while safeguarding public health. Although these 
laws and regulations should create a strong foundation for TB-IC, poor TB-IC 
implementation2 and scant data on occupational TB from LMICs such as these9 suggests 
otherwise. Future research should assess the implementation and public health impact of 
laws and regulations regarding TB-IC.
Laws such as the Occupational Health and Safety Act (OHSA) in South Africa76 classify TB 
as an occupational disease, which means that HCWs who develop TB should receive 
compensation, including occupational sick leave, medical expenses, permanent disability 
payments and payments to surviving family members. Unfortunately students, CHWs and 
volunteers with the same exposures typically do not receive the same legal protection despite 
suffering the same devastating consequences45. Legal frameworks must be strengthened to 
ensure that TB-IC measures are implemented, monitored and evaluated as recommended and 
to provide care and compensation to all HCWs including trainees and volunteers who are 
affected by occupational TB. This is an ethical imperative for policy makers77.
ONGOING SCIENTIFIC CHALLENGES
It is estimated that 1.7 billion people globally are infected with TB78. Certain risk factors 
that increase the likelihood of developing active TB have been identified such as HIV, 
diabetes and tobacco use. However, in other populations that include HCWs, who are more 
likely to have latent TB infection (LTBI) than the general population24, it is not possible to 
predict who will develop active TB. IPT or alternative LTBI treatment regimens have been 
recommended in high and low incidence settings for groups at high risk of TB reactivation, 
such as people living with HIV and contacts of patients with pulmonary TB79. However, 
there is currently no guidance for HIV-uninfected HCWs (or other HIV-uninfected 
individuals) in HBCs who are at frequent risk of re-exposure and re-infection80. This is the 
subject of debate but based on evidence that treatment of LTBI decreases the risk of future 
reactivation to TB disease62–64 resulting in this being a policy recommendation for low-
incidence countries81, preventive therapy should be recommended and available for HCWs 
as well as others in HBCs with TB infection despite their re-exposure and re-infection risk. 
Due to the increasing incidence of MDR- and XDR-TB, there are increasing numbers of 
people (including HCWs) with latent DR-TB, but there are no guidelines regarding 
preventive therapy for DR-TB exposure. Although HCWs in HBCs will typically have 
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received the Mycobacterium bovis Bacille Calmette-Guérin (BCG) vaccine as part of the 
childhood immunization series, the effectiveness of this vaccine is primarily to reduce the 
risk of TB meningitis in infants. Data suggests that BCG also reduces the risk of infection82, 
but BCG immunity subsequently wanes over time, such that vaccination does not prevent 
adults from developing TB83. Due to the complex biology of Mycobacterium tuberculosis, 
multiple vaccine strategies are being pursued to a) prevent TB infection after initial 
exposure, b) prevent the development of TB disease in those who are infected but 
asymptomatic and c) to prevent recurrent disease in those who have developed and been 
treated for TB disease84.
CONCLUSIONS
TB elimination efforts cannot succeed without increased attention and resources being 
channeled towards TB-IC and occupational health systems strengthening. Table 1 
demonstrates suggested action points at the individual healthcare facility, National TB 
Programme and supranational WHO level that are critical to decrease nosocomial TB 
transmission, which includes occupational TB. A focus on monitoring and evaluating TB-IC 
interventions is needed to ensure that meaningful improvements are being made. HCWs are 
uniquely placed as agents of change to raise awareness and decrease stigma regarding 
occupational TB, advocate for policies supported by legislation and critically to act by 
implementing the solutions discussed in this review. This can lead to healthcare facilities 
becoming safer for both HCWs and the patients they serve and enabling the delivery of 
higher quality care even in under-resourced high TB burden countries. Strong leadership 
coupled with sustained political commitment, supportive legislative frameworks and 
adequate financial investment will be critical to achieve these goals.
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Figure 1. 
TB Proof awareness and advocacy session, Faculty of Medicine and Health Sciences, 
Stellenbosch University, Cape Town, South Africa.
Picture credit: TB Proof.
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Table 1
Suggested Action Points
Level of Health System Suggested Actions
Local Facility -Establish a TB-IC plan in accordance with WHO checklist guidelines with regular monitoring and evaluation 
(M&E).
-Provide training to and support for dedicated TB-IC officers.
-Develop peer education sessions that may be strengthened by advocacy from occupational TB survivors.
-Implement Occupational Health Programmes that include testing HCWs for development of latent TB infection 
and active TB disease and providing treatment for both, along with linkage to HIV testing and care. 
Confidentiality should be assured wherever possible but not preclude contact evaluation.
-Occupation should be recorded on TB registry forms.
-Identify high-risk areas that are poorly ventilated or overcrowded for mitigation by changing patient flow and/or 
implementing strategies such as mechanical ventilation and/or germicidal ultraviolet air disinfection.
-Ensure that fit-tested respirators are available for all staff working in clinical areas, including students.
National TB Programme -Ensure robust M&E programmes for TB-IC and Occupational Health Programmes.
-Include community health workers, at-risk non-clinical hospital staff and students in these programmes and 
ensure that they receive adequate training.
-Institute and utilize supportive legal frameworks to ensure that TB-IC implementation occurs along with 
requisite M&E.
-Ensure access to diagnostic testing and treatment for latent and active TB.
WHO -Record annual numbers of HCWs that develop TB infection and disease based on facility case records that 
should include occupation as an indicator.
-Provide guidance regarding legal frameworks to support TB-IC and occupational health programmes.
-Provide guidance regarding preventive therapy for HIV uninfected HCWs, including those who may have been 
exposed to DR-TB.
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